Diagnosis of RA according to the ACR/EULAR 2010 criteria without a history of cardiovascular diseases, Rheumatroid Arthritis
Conditions
Brief summary
The main study parameter is the change in LV function in RA patients after 1 year of treatment with filgotinib. LV function will be assessed at baseline and follow-up using CMR measurements of global circumferential, longitudinal and radial strain
Detailed description
The comparisons between baseline and follow-up data in RA patients treated with filgotinib for 1 year. And comparisons between RA patients and age- and sex-matched healthy volunteers. The first category is subdivided into endpoints derived from CMR, endpoints derived from CCTA, and endpoints concerning clinical treatment evaluation. The second category is subdivided into endpoints derived from CMR and endpoints derived from CCTA.
Interventions
Sponsors
Reade revalidatie & reumatologie centrum te Amsterdam
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the change in LV function in RA patients after 1 year of treatment with filgotinib. LV function will be assessed at baseline and follow-up using CMR measurements of global circumferential, longitudinal and radial strain | — |
Secondary
| Measure | Time frame |
|---|---|
| The comparisons between baseline and follow-up data in RA patients treated with filgotinib for 1 year. And comparisons between RA patients and age- and sex-matched healthy volunteers. The first category is subdivided into endpoints derived from CMR, endpoints derived from CCTA, and endpoints concerning clinical treatment evaluation. The second category is subdivided into endpoints derived from CMR and endpoints derived from CCTA. | — |
Countries
Netherlands
Outcome results
None listed